Benralizumab
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Benralizumab: From Its Approved Use to Thrombocytopenia Due to Immune Destruction
One-Sentence Summary
Benralizumab is an anti-IL-5Rα antibody marketed in the US as FASENRA. The source record does not state its approved indication. The TxGNN model predicts it may be effective for thrombocytopenia due to immune destruction, but no clinical trials and no publications support this prediction, so it is a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the source record |
| Predicted New Indication | Thrombocytopenia due to immune destruction |
| TxGNN Prediction Score | 99.34% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 3 (all records are BLA761070) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Benralizumab is an anti-IL-5Rα antibody that depletes eosinophils and basophils. Detailed mechanism-of-action data are not available in the source record.
No clear pathway links this mechanism to antibody-mediated platelet destruction. Immune thrombocytopenia is driven by autoantibodies and clearance of platelets, not by the IL-5/eosinophil axis. The high score most likely reflects proximity in the knowledge graph rather than a proven biological link, so the prediction should be treated as a hypothesis only.
Other predictions for this drug offer context. For dermatitis (rank 2), a placebo-controlled Phase 2 trial in atopic dermatitis (HILLIER) found no clinical benefit, even though biopsy data show the drug depletes IL-5Rα-bearing cells in skin. This is a reminder that target engagement does not guarantee efficacy. The remaining top predictions (acne keloid, neonatal dermatomyositis, amyopathic dermatomyositis) also have no supporting studies.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| BLA761070 | FASENRA (AstraZeneca Pharmaceuticals LP) | Injection, solution | Not stated in the source record |
The three license records in the source record share the same authorization number and product. Only the injectable route is available.
Safety Considerations
Please refer to the package insert for safety information. No drug-drug interaction records were found.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on the model score alone (L5), with no trials or publications. There is no plausible mechanistic link between IL-5Rα blockade and immune-mediated platelet destruction. The nearest related prediction, atopic dermatitis, has already shown a negative randomized result despite target engagement.
To proceed, the following is needed:
- Mechanism-of-action data and a mechanistic rationale connecting eosinophil or basophil depletion to platelet destruction
- A targeted literature and trial-registry search for benralizumab in immune thrombocytopenia, including case reports
- The FDA package insert (approved indication, warnings, contraindications) to complete safety screening
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.